Author Contributions: Dr de Lemos had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: de Lemos, McGuire.
Acquisition of data: de Lemos, Khera, Hashim, McGuire.
Analysis and interpretation of data: de Lemos, Drazner, Omland, Ayers, Khera, Rohatgi, Berry, Das, Morrow, McGuire.
Drafting of the manuscript: de Lemos.
Critical revision of the manuscript for important intellectual content: de Lemos, Drazner, Omland, Ayers, Khera, Rohatgi, Hashim, Berry, Das, Morrow, McGuire.
Statistical analysis: Ayers.
Obtained funding: de Lemos, McGuire.
Administrative, technical, or material support: Hashim.
Study supervision: de Lemos.
Financial Disclosures: Dr de Lemos reported receiving research grants from Roche Diagnostics and Biosite/Inverness and receiving consulting fees and/or lecture honoraria from Tethys Biomedical, Johnson & Johnson, Roche Diagnostics, Biosite/Inverness, Siemens, AstraZeneca, Pfizer, BMS/sanofi-aventis, and Merck/Schering. Dr Drazner reported receiving consulting fees from Biosite/Inverness and lecture honoraria from GlaxoSmithKline. Dr Omland reported receiving research support and lecture honoraria from Roche Diagnostics and Abbott Laboratories. Dr Morrow reported receiving honoraria for educational presentations from Beckman-Coulter, CV Therapeutics, and Eli Lilly and receiving consulting fees from Beckman-Coulter, Boerhinger Ingelheim, Instrumentation Laboratories, Menarini, Merck, sanofi-aventis, Servier, Roche Diagnostics, Siemens, and AstraZeneca. The TIMI Study Group, which supports Dr Morrow's salary, has received significant research grant support from Accumetrics, Amgen, AstraZeneca, Beckman Coulter, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo Co Ltd, Eli Lilly and Co, GlaxoSmithKline, Integrated Therapeutics, Merck and Co, Merck-Schering Plough Joint Venture, Nanosphere, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, sanofi-aventis, Siemens, and Singulex. Dr McGuire reported receiving grant support from GlaxoSmithKline; receiving consulting fees from Tethys Bioscience, Biosite, F. Hoffmann LaRoche/Genentech, Cardiovascular Therapeutics, AstraZeneca, Novo Nordisk, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Johnson & Johnson, and sanofi-aventis; and receiving lecture honoraria from Pfizer and Takeda. No other authors reported disclosures.
Funding/Support: Grant support for the Dallas Heart Study was provided by the Donald W. Reynolds Foundation and by US Public Health Service General Clinical Research Center grant M01-RR00633 from National Institutes of Health (NIH)/NCRR-CR. This study was supported in part by the North and Central Texas Clinical and Translational Science Initiative (NIH grant UL1 RR024982). Financial and materials support for measurements of cardiac troponin T (cTnT) levels in the present study were provided by Roche Diagnostics (Indianapolis, Indiana). Roche Diagnostics also previously provided materials and support for measurement of levels of cTnT, N-terminal pro-brain-type natriuretic peptide, and C-reactive protein in the Dallas Heart Study.
Role of the Sponsor: Roche Diagnostics and the NIH had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Additional Contributions: We thank Jerry Ashmore, MT, and Barbara Morgan, MT, BS, MEd, for performing the highly sensitive cardiac troponin T assays and Helen Hobbs, MD, Teresa Eversole, BS, and Kathleen Wilkinson, MS, for their leadership of the Dallas Heart Study. The affiliation for all additional contributors listed is University of Texas Southwestern Medical Center, Dallas. Partial salary support was provided to Barbara Morgan and Jerry Ashmore.